Worldwide Clinical Trials

APRIL 25, 2024

Authors: Rolana Avrumson, MS, VP Clinical Projects, Clinical Assessment Technologies; Barry Dussault Executive Director, Project Management, Franchise Area Lead, Pain Upwards of 58% of patients experience moderate to severe post-surgical pain, while some research places that figure even higher at a staggering 80%. These data highlight both the prevalence of post-surgical pain and the critical need for comprehensive, non-opioid treatments aimed at alleviating it.

Clinical Trials 130

Clinical Trials Clinical Trials Compliance Trials 130

Bio Pharma Dive

APRIL 25, 2024

The layoffs will impact some 2,200 employees, the company said, as it repositions its business ahead of looming patent expirations for top-selling products.

Drugs 311

Drugs Production 311

Pharmaceutical Technology

APRIL 25, 2024

Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.

246

246

Bio Pharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

Gene Editing 311

Gene Editing Gene Genetics Medicine 311

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 25, 2024

Researchers have identified dysfunctions in two specific brain systems in people who have psychosis – systems that help us filter attention to important internal and external information and predict or anticipate rewards.

Scientist 241

Scientist Research Clinical Trials Clinical Trials 241

Bio Pharma Dive

APRIL 25, 2024

The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.

Gene Therapy 303

Gene Therapy Gene Drugs 303

Bio Pharma Dive

APRIL 25, 2024

The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.

Medicine 189

Medicine Drugs 189

Pharmaceutical Technology

APRIL 25, 2024

Merck has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at its global headquarters in Darmstadt, Germany.

Life Science 147

Life Science Research 147

Pharma Times

APRIL 25, 2024

The tool will help people find out about clinical trials for myeloma, MGUS, SMM and AL amyloidosis

Clinical Trials 136

Clinical Trials Clinical Trials Trials 136

Pharmaceutical Technology

APRIL 25, 2024

A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.

Drugs 130

Drugs 130

Advertisement

Clinical Supply

Pharma Times

APRIL 25, 2024

X-linked Charcot-Marie-Tooth is the second most common form of the rare peripheral neuropathy disease

Research 122

Research 122

Pharmaceutical Technology

APRIL 25, 2024

The first episode in Sterling's podcast series on digital dealmaking in life sciences puts a spotlight on corporate culture

Life Science 130

Life Science 130

Fierce Pharma

APRIL 25, 2024

Merck touted newly approved Winrevair and what the emergence of the potential blockbuster means for the company as it faces the LOE of Keytruda.

Marketing 122

Marketing 122

Pharmaceutical Technology

APRIL 25, 2024

Mundipharma is to acquire all assets and rights related to antifungal candidate Rezzayo (rezafungin) from Cidara Therapeutics.

130

130

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Fierce Pharma

APRIL 25, 2024

Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs of their drugs, Sen. | Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co. and Johnson & Johnson about the high costs of their drugs, Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.

Drugs 119

Drugs 119

Pharmaceutical Technology

APRIL 25, 2024

The FDA has approved Utility Therapeutics’ Pivya tablets, a new treatment for female adults with UTIs.

FDA Approval 130

FDA Approval 130

Fierce Pharma

APRIL 25, 2024

After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin. | After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.

Vaccination 116

Vaccination Vaccine 116

Pharmaceutical Technology

APRIL 25, 2024

Biogen has reported net income of $393.4m for the first quarter (Q1) of 2024, an increase from $387.6m in the same period a year ago.

130

130

Advertisement

Clinical Supply

XTalks

APRIL 25, 2024

Heart failure, affecting over 64 million people worldwide , remains a formidable challenge in the medical community despite advancements in pharmacotherapy over the past decade. The prognosis for heart failure patients is disheartening, with a mere half surviving beyond five years post-diagnosis. This stark reality highlights the urgent need for novel heart failure management options, particularly for advanced stages of the disease.

Development 111

Development Trials Clinical Trials Clinical Trials 111

Pharmaceutical Technology

APRIL 25, 2024

Speakers discuss how SMEs can attract capital after a rise in investment activity in Q1 2024 compared to the last quarter of 2023.

Life Science 130

Life Science 130

BioSpace

APRIL 25, 2024

Pfizer will go toe-to-toe with CSL Behring following the FDA’s Friday approval of its hemophilia B gene therapy Beqvez and will launch a warranty program based on the durability of response.

Gene Therapy 107

Gene Therapy Gene FDA Approval 107

pharmaphorum

APRIL 25, 2024

On today’s podcast, host Jonah Comstock is joined by Dr Amit Etkin, founder and CEO of Alto Neuroscience, a recently IPO'd biotech that wants to bring precision medicine to psychiatry. But what do we mean when we talk about precision, especially in a discipline like mental health that has historically involved a lot of objectivity?

Medicine 107

Medicine 107

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Fierce Pharma

APRIL 25, 2024

Facing pressure from the Inflation Reduction Act (IRA) and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO Chris Boerner, Ph.D., still says the Breyanzi-maker h | Facing pressure from the Inflation Reduction Act and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO Chris Boerner says the Beyenzi-maker had a "good start" with the first quarter.

Sales 105

Sales 105

Pharmaceutical Commerce

APRIL 25, 2024

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

Manufacturing 105

Manufacturing Production 105

Fierce Pharma

APRIL 25, 2024

For the first time in more than 20 years, the FDA has approved a | For the first time in more than 20 years, the FDA has approved a treatment for uncomplicated urinary tract infections. And the endorsement has come for an oral antibiotic that has been available in Europe for more than 40 years. It’s an odd set of circumstances and a dose of foresight by Utility Therapeutics that bring Pivya (pivmecillinam) to the market in the United States in the therapy’s golden years.

Marketing 98

Marketing 98

Pharmaceutical Commerce

APRIL 25, 2024

The latest news for pharma industry insiders.

Pharmacy 103

Pharmacy Vaccination Vaccine Research 103

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Fierce Pharma

APRIL 25, 2024

Where innovation meets obstacles and the cost of drug development skyrockets, the key to unlocking success of groundbreaking products in the biopharma industry will rely heavily on strategic | Collaborative partnerships key to clearing the path for new biopharma products

Production 98

Production Development Drugs 98

Outsourcing Pharma

APRIL 25, 2024

Wuxi AppTec says recent allegations made by the US government that it has shared clients' data with Beijing without consent are âmisleadingâ and âinaccurateâ.

Regulation 95

Regulation Marketing 95

Fierce Pharma

APRIL 25, 2024

Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. | Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. A depression drug candidate that Neurocrine licensed from Takeda succeeded in a phase 2 trial. AstraZeneca and Daiichi Sankyo's Enhertu is on the cusp of a key readout in HER2-low breast cancer.

Licensing 98

Licensing Licensing Trials Drugs 98

BioSpace

APRIL 25, 2024

The genetic engineering startup, recently honored by BioSpace readers for its work environment, is downsizing as it seeks to launch its first clinical trials.

Genetic Engineering 94

Genetic Engineering Engineer Clinical Trials Clinical Trials 94

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials